We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.52B
$9.21M 0.04%
427,179
– –
ISEE
77
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.69M 0.04%
1,406,037
– –
NGM
78
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$8.48M 0.04%
291,801
+185,185
+174% +$5.18M
KRTX
79
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.41M 0.04%
69,966
– –
GMDA
80
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.39M 0.04%
1,037,226
-511,088
-33% -$4.69M
ASMB icon
81
Assembly Biosciences
ASMB
$493M
$7.09M 0.03%
128,452
– –
CABA icon
82
Cabaletta Bio
CABA
$430M
$7.06M 0.03%
636,363
– –
BLUE
83
DELISTED
bluebird bio
BLUE
$6.84M 0.03%
17,523
– –
MGNX icon
84
MacroGenics
MGNX
$235M
$6.39M 0.03%
200,679
– –
BNR
85
Burning Rock Biotech
BNR
$94M
$5.63M 0.02%
20,913
– –
NEXI
86
DELISTED
NexImmune, Inc. Common Stock
NEXI
$5.61M 0.02%
+11,765
New +$6.4M
SGMO
87
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.38M 0.02%
429,063
-428,276
-50% -$5.77M
ORTX
88
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.33M 0.02%
73,443
+40,193
+121% +$2.85M
SYRS
89
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.16M 0.02%
69,017
– –
ITOS
90
DELISTED
iTeos Therapeutics
ITOS
$5.14M 0.02%
150,346
– –
DNLI icon
91
Denali Therapeutics
DNLI
$3.76B
$5.07M 0.02%
88,738
– –
ALEC icon
92
Alector
ALEC
$169M
$4.82M 0.02%
239,228
– –
EVFM
93
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.72M 0.02%
179,807
+152,381
+556% +$6.93M
REPL icon
94
Replimune Group
REPL
$424M
$4.68M 0.02%
153,512
– –
TVTX icon
95
Travere Therapeutics
TVTX
$5.13B
$4.67M 0.02%
+186,915
New +$5.16M
SRPT icon
96
Sarepta Therapeutics
SRPT
$1.65B
$4.38M 0.02%
+58,700
New +$5.42M
PASG icon
97
Passage Bio
PASG
$14.2M
$4.11M 0.02%
11,768
– –
HRMY icon
98
Harmony Biosciences
HRMY
$2.07B
$4.08M 0.02%
123,600
-56,400
-31% -$1.98M
TCRR
99
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.9M 0.02%
176,461
+65,573
+59% +$1.79M
TCDA
100
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.86M 0.02%
729,300
+100,000
+16% +$628K
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.